^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    MLH3 overexpression + HR positive

    i
    Other names: MLH3, MutL Homolog 3, DNA Mismatch Repair Protein Mlh3, MutL (E. Coli) Homolog 3, MutL Homolog 3 (E. Coli), MutL Protein Homolog 3, HNPCC7, ESR1, Era, ESR, NR3A1, ER, ER beta, PGR, Progesterone receptor, Nuclear receptor subfamily 3 group C member 3, NR3C3
    Entrez ID:
    2099; 5241; 27030
    Related biomarkers:
    Expression
    Mutation
    CNA
    Fusion
    Others
    1year
    DNA damage response in circulating tumor cells shows predictive value for metastatic breast cancer patients receiving CDK4/6 inhibitors (AACR 2023)
    Background: Resistance to CDK4/6 inhibitors (CDK4/6i), like Palbociclib and Ribociclib, plus endocrine therapy (TX) is an omnipresent topic for metastatic (M), hormone receptor-positive/HER2-negative (HR+/HER2-) breast cancer (BC) patients (pts). We identified overexpression of transcripts involved in DNA damage response mechanisms (CETN2, MLH3 and/or PCNA) at baseline to have predictive and/or prognostic value in first line CDK4/6i treated pts while signal dynamics of CETN2 and PCNA to six months of TX could serve as monitoring marker in these pts. Currently, further longitudinal blood sampling over the course of treatment is underway to give a deeper insight in resistance development under CDK4/6i treatment.
    Clinical • Circulating tumor cells • Tumor cell • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • CXCR4 (Chemokine (C-X-C motif) receptor 4) • PTPRC (Protein Tyrosine Phosphatase Receptor Type C) • PCNA (Proliferating cell nuclear antigen) • STAT1 (Signal Transducer And Activator Of Transcription 1) • WWTR1 (WW Domain Containing Transcription Regulator 1) • E2F1 (E2F transcription factor 1)
    |
    HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative • CETN2 overexpression + HR positive • CETN2 overexpression + MLH3 overexpression + PCNA overexpression + HR positive • MLH3 overexpression + HR positive • PCNA overexpression + HR positive
    |
    Ibrance (palbociclib) • Kisqali (ribociclib)